Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.89 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.54 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.42 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.42 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Batilol SCHEMBL940982 | 1.00 | USP2 (0.89) | USP2HTTLPAR5PLA2G2CMEN1 | |
| Ether SCHEMBL6805057 | 1.00 | USP2 (0.89) | USP2HTTLPAR5PLA2G2CMEN1 | |
| Ether SCHEMBL2015031 | 1.00 | USP2 (0.89) | USP2HTTLPAR5PLA2G2CMEN1 | |
| Ether SCHEMBL8501744 | 1.00 | USP2 (0.89) | USP2HTTLPAR5PLA2G2CMEN1 | |
| Ether SCHEMBL6428915 | 1.00 | USP2 (0.89) | USP2HTTLPAR5PLA2G2CMEN1 | |
| Ether SCHEMBL2390477 | 1.00 | USP2 (0.89) | USP2HTTLPAR5PLA2G2CMEN1 | |
| Ether SCHEMBL8502252 | 1.00 | USP2 (0.89) | USP2HTTLPAR5PLA2G2CMEN1 | |
| Ether SCHEMBL3811088 | 1.00 | USP2 (0.89) | USP2HTTLPAR5PLA2G2CMEN1 | |
| Ether SCHEMBL8501725 | 0.98 | USP2 (0.85) | USP2HTTLPAR5PLA2G2CMEN1 | |
| SCHEMBL24835077 | 0.94 | USP2 (1.00) | USP2HTTLPAR5PLA2G2CMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040208783-A1 | Process for the chemical and thermal disinfection | AIR LIQUIDE SANTE (INTERNATIONAL ) (FR) | 2004-10-21 | — | — | US | claimed |
| EP-1468606-A1 | Process for the chemical and thermal disinfection | Air Liquide Santé (International) (FR) | 2004-10-20 | — | — | EP | claimed |
| CN-102040621-B | Lipid oxide and the application in treatment inflammatory diseases thereof | CANALIS-HAEMALIS BIOGROWTH LTD. (IL) | 2016-01-20 | — | — | CN | disclosed |
| US-8563534-B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2013-10-22 | — | — | US | disclosed |
| US-8501715-B2 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD. (IL) | 2013-08-06 | — | — | US | disclosed |
| EP-1626728-B1 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD (IL) | 2013-07-10 | — | — | EP | disclosed |
| US-20120329757-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2012-12-27 | — | — | US | disclosed |
| CN-102666811-A | Compositions and methods for reducing friction in internal combustion engines | BP CORP NORTH AMERICA INC | 2012-09-12 | — | — | CN | disclosed |
| US-8158611-B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2012-04-17 | — | — | US | disclosed |
| EP-2425841-A1 | Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis | Vascular Biogenics Ltd. (IL) | 2012-03-07 | — | — | EP | disclosed |
| US-20110189212-A1 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD. (IL) | 2011-08-04 | — | — | US | disclosed |
| WO-2004106486-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD. (IL) | 2004-12-09 | — | — | WO | disclosed |
| US-20040106677-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2004-06-03 | — | — | US | disclosed |
| US-20030225035-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. | 2003-12-04 | — | — | US | disclosed |
| EP-1341543-A2 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | Vascular Biogenics Ltd. (IL) | 2003-09-10 | — | — | EP | disclosed |
| US-6596763-B1 | Method for counteracting infections caused by bacteria, fungi or virus such as Herpes Simplex Virus in skin or mucosal membranes, in particular genital membranes, of a mammal. The method comprises topically administering to skin or mucous | LIPOMEDICA EHF. (IS) | 2003-07-22 | — | — | US | disclosed |
| WO-2002041827-A9 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | VASCULAR BIOGENICS LTD (IL) | 2003-05-30 | — | — | WO | disclosed |
| WO-2002041827-A2 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | VASCULAR BIOGENICS LTD. (IL) | 2002-05-30 | — | — | WO | disclosed |
| EP-0941087-A1 | TOPICAL FORMULATIONS CONTAINING AS A THERAPEUTIC ACTIVE AGENT FATTY ACIDS OR FATTY ALCOHOLS OR MONOGLYCERIDE DERIVATIVES THEREOF FOR TREATING OF MUCOSA INFECTIONS | Thormar, Halldor (IS) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998020872-A1 | TOPICAL FORMULATIONS CONTAINING AS A THERAPEUTIC ACTIVE AGENT FATTY ACIDS OR FATTY ALCOHOLS OR MONOGLYCERIDE DERIVATIVES THEREOF FOR TREATING OF MUCOSA INFECTIONS | THORMAR HALLDOR (IS) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189212-A1 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | ALOX15B, GPX4, ALOX12 | USP2 1937/4885HTT 2290/4885LPAR5 292/4885 |
| US-20120329757-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | USP2 1194/4885HTT 4544/4885LPAR5 292/4885 |
| US-20030225035-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | USP2 1194/4885HTT 4544/4885LPAR5 292/4885 |
| US-20040106677-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | USP2 1194/4885HTT 4544/4885LPAR5 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.